Clinical Trials
Open
Phase
III
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Status Notes
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Research Committee(s)
Genitourinary Cancer
Activated
05-01-2021
ClinicalTrials.gov Registry Number
NCT04637594
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA8185
Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Status Notes
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Research Committee(s)
Genitourinary Cancer
Activated
05-01-2021
ClinicalTrials.gov Registry Number
NCT04216290
Open
Phase
II
Accrual
4%
SWOG Clinical Trial Number
S1900E
A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Status Notes
S1900E will open to accrual April 2, 2021, effective 12:00 pm PST.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
04-02-2021
Open
Phase
II-III
Accrual
0%
SWOG Clinical Trial Number
S1918
A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
Status Notes
Activation - Effective 3/19/21, 12:00 pm Pacific Time
Training for Conduct of FIL Tool, accessible from: https://www.swog.org/required-s1918-training.
Online FIL Tool, accessible from: https://redcap.filinf.it/surveys/?s=RF4FPKH799.
Note: Responses must also be submitted in iMedidata RAVE, as indicated in protocol Section 14.5a, along with the score generated by the online FIL Tool.
Training for Conduct of FIL Tool, accessible from: https://www.swog.org/required-s1918-training.
Online FIL Tool, accessible from: https://redcap.filinf.it/surveys/?s=RF4FPKH799.
Note: Responses must also be submitted in iMedidata RAVE, as indicated in protocol Section 14.5a, along with the score generated by the online FIL Tool.
Research Committee(s)
Lymphoma
Activated
03-19-2021
ClinicalTrials.gov Registry Number
04799275
Open
Phase
III
Accrual
0%
SWOG Clinical Trial Number
S1937
A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.
Status Notes
This study is open to accrual effective February 16, 2021.
Research Committee(s)
Genitourinary Cancer
Activated
02-16-2021
ClinicalTrials.gov Registry Number
NCT04579224
Open
Phase
III
SWOG Clinical Trial Number
CTSU/A011801
The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in Her2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
01-06-2021
ClinicalTrials.gov Registry Number
04457596